Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX

• https://x.com/RichardPAConway/status/1983230783952466190/photo/1

In a 4-year study of 85 SpA patients, ChatGPT-4o matched SPSS in analyzing NLR/PLR trends. Outputs were identical, but ChatGPT offered faster interpretation and clinical context, highlighting AI’s potential to streamline early-stage research. Abstract#2354 @RheumNow #ACR25 https://t.co/W3pPQijPBD

• https://x.com/synovialjoints/status/1983224744808984704/photo/1

ROC-SpA study assessed whether changing to an IL-17Ai was superior to rotating to a 2nd TNFi in axSpA pts who failed on a 1st TNFi At wk 24, no significant diff in ASAS40 rates bet the 2 groups IL-17Ai not superior to a 2nd TNFi Rotate or change? #ACR25 @Rheumnow AbsLB09 https://t.co/4EtNEFTSN9

• https://x.com/RHEUMarampa/status/1983217242008388002/photo/1

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

• https://x.com/AkhilSoodMD/status/1983203353975808401/photo/1

Is taking NSAIDs +TNFi better for the joints? Abstract 2359: In radiographic axSpA, NSAIDS + TNFi associated with -fewer syndesmophytes 36% vs 58% TNFi - no significant effect on hip structural changes - @RheumNow #ACR25

In case you have a (gut) feeling something’s off… Abstract 2315: The gut microbiome in #SpA 🔬 ⬆️ Proteobacteria (incl. Escherichia spp) ⬇️ Firmicutes (“good” bacteria) Higher disease activity ↔️ lower alpha diversity @RheumNow #ACR25

Zavada et al. 52 patients. bDMARD therapy improves sexual function at 6 months in r-axSpA. Improvements in function, desire, satisfaction in those with baseline erectile dysfunction @RheumNow #ACR25 Abstr#2346 https://t.co/IUMGCFnXZh

• https://x.com/RichardPAConway/status/1983196810190696712/photo/1

Konsta et al. Adding NSAID to TNF inhibits spinal but not hip radiograpic progress. 262 patients, TNF+NSAID 100, TNF alone 162. New syndesmophytes 36% vs 58%. ΔmSASSS-score/year 0.1 vs 0.7. No effect on progression of hip radiographs. @RheumNow #ACR25 Abstr#2359 #ACRBest https://t.co/k9j2M2E3ze

• https://x.com/RichardPAConway/status/1983196307096297889/photo/1

Macedo et al. Increasing exercise improved QoL in axSpA. Mobility limitation and obesity worsened it. At least to some degree these effects appear independent. @RheumNow #ACR25 Abstr#2326 https://t.co/Ei4cKTNHyn

• https://x.com/RichardPAConway/status/1983194545300099396/photo/1

Gender differences in p/axSpA in Turkiye from ASAS-PerSpA: Males - early onset IBP (<45yrs); sacroiliitis on CR, HLA-B27+ (vs. females) Females - peripheral dse, enthesitis, Pso, dactylitis; ⬆️dse activity, FM (vs. males) Individualize & optimize tx. #ACR25 @RheumNow Abs2322 https://t.co/vcisNguJLB

• https://x.com/RHEUMarampa/status/1983190266963202058/photo/1

Rotation or Change in Biologic post TNFi failure in axSpA. Switching biologic class after TNFi failure improved outcomes in axial SpA. In a randomized trial of axSpA patients with inadequate response to a first TNFi, switching to an IL-17Ai was not superior to cycling to a second https://t.co/MEsokWeT8e

• https://x.com/synovialjoints/status/1983187006759846067/photo/1

This cohort study from Ontario of 🚺w/axSpA ✳️GDM, antepartum hem, SMM (severe maternal morbidity) -⬆️ in axSpA ✳️Neonat complications-preterm birth Factors assoc w/SMM- age, comorbidity, gestational age at delivery Better strategies for maternal care #ACR25 @RheumNow Abs2200 https://t.co/LrVzJLnvWe

• https://x.com/RHEUMarampa/status/1983187000585834686/photo/1
• https://x.com/RHEUMarampa/status/1983187000585834686/photo/1

Late-Breaking Trials in axSpA and PsA https://t.co/Fw8wiAPLoN The amazing @Janetbirdope discussing head to head trials in Axial SpA and PsA with primary failure to TNF. To switch to another TNF or IL17? IL17 for my PsA patient for sure. @RheumNow #ACR25

• Late-Breaking Trials in axSpA and PsA